Akira Kato - Shionogi Executive Officer
| SGIOF Stock | USD 14.10 1.69 13.62% |
Executive
Akira Kato is Executive Officer of Shionogi Co
| Phone | 81 6 6202 2161 |
| Web | https://www.shionogi.com |
Shionogi Management Efficiency
The company has return on total asset (ROA) of 0.1067 % which means that it generated a profit of $0.1067 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.2014 %, meaning that it generated $0.2014 on every $100 dollars invested by stockholders. Shionogi's management efficiency ratios could be used to measure how well Shionogi manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Ramsey Alloush | Journey Medical Corp | 38 | |
| Bill Iskos | Assertio Therapeutics | N/A | |
| John Keller | Shionogi Co Ltd | 58 | |
| Paul Schwichtenberg | Assertio Therapeutics | 53 | |
| Dennis McLoughlin | Pacira BioSciences, | 58 | |
| Michelle Lefler | Aurora Cannabis | N/A | |
| MD MBA | Assertio Therapeutics | N/A | |
| Allan Cleiren | Aurora Cannabis | N/A | |
| Eric Benevich | Neurocrine Biosciences | 59 | |
| Marcel Moulaison | Ironwood Pharmaceuticals | N/A | |
| Ryuichi Kiyama | Shionogi Co Ltd | N/A | |
| Max Reinhardt | Pacira BioSciences, | 53 | |
| Michael MD | Ironwood Pharmaceuticals | 65 | |
| Greg Martini | Ironwood Pharmaceuticals | N/A | |
| Jaclyn Jaffe | Journey Medical Corp | N/A | |
| Darin Lippoldt | Neurocrine Biosciences | 58 | |
| Simona CPA | Aurora Cannabis | 52 | |
| Charles Laranjeira | Pacira BioSciences, | 58 | |
| Ronald Silver | Ironwood Pharmaceuticals | 41 | |
| Malek Chamoun | Sunshine Biopharma | 39 | |
| Glenn Brame | Esperion Therapeutics | 66 | |
Management Performance
Shionogi Leadership Team
Elected by the shareholders, the Shionogi's board of directors comprises two types of representatives: Shionogi inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Shionogi. The board's role is to monitor Shionogi's management team and ensure that shareholders' interests are well served. Shionogi's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Shionogi's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Kohji Hanasaki, Sr Division | ||
| Isao Teshirogi, CEO and President and Representative Director | ||
| Kazuhiro Hatanaka, Executive Officer | ||
| Ryuichi Kiyama, Executive Officer | ||
| Yoshihiro Furuya, VP Office | ||
| John Keller, Executive Officer | ||
| Takeshi Shiota, Executive Officer | ||
| Akira Kato, Executive Officer | ||
| Susumu Mitsumori, VP Department | ||
| Yoshimasa Kyokawa, VP Office |
Shionogi Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Shionogi a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.2 | |||
| Return On Asset | 0.11 | |||
| Profit Margin | 0.44 % | |||
| Operating Margin | 0.43 % | |||
| Current Valuation | 11.39 B | |||
| Shares Outstanding | 298.16 M | |||
| Shares Owned By Insiders | 4.66 % | |||
| Shares Owned By Institutions | 52.78 % | |||
| Price To Earning | 15.47 X | |||
| Price To Book | 2.01 X |
Currently Active Assets on Macroaxis
Other Information on Investing in Shionogi Pink Sheet
Shionogi financial ratios help investors to determine whether Shionogi Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Shionogi with respect to the benefits of owning Shionogi security.